DexCom Reports Director/Officer Changes & Compensation

Ticker: DXCM · Form: 8-K · Filed: 2025-05-13T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-changes, director-changes, compensation

Related Tickers: DXCM

TL;DR

DexCom filed an 8-K detailing director/officer changes and compensation arrangements.

AI Summary

DexCom, Inc. filed an 8-K on May 13, 2025, reporting events as of May 9, 2025. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.

Why It Matters

Changes in a company's board of directors and executive officers, along with details on their compensation, can signal shifts in strategy or governance that may impact investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing is routine and reports on corporate governance and compensation, not immediate financial distress or significant operational changes.

Key Players & Entities

FAQ

What specific director or officer positions were affected by the events reported on May 9, 2025?

The filing indicates changes related to the departure of directors or certain officers, election of directors, and appointment of certain officers, but does not specify names or exact positions within this summary.

What type of compensatory arrangements are detailed in this filing?

The filing mentions 'Compensatory Arrangements of Certain Officers' but does not provide specific details on the nature of these arrangements in the provided text.

Are there any new financial statements included with this 8-K filing?

Yes, the filing explicitly lists 'Financial Statements and Exhibits' as an item of information.

What is the primary purpose of this Form 8-K filing for DexCom, Inc.?

The primary purpose is to report current information about significant corporate events, including changes in directors and officers, and related compensation matters.

When was DexCom, Inc. incorporated, and where are its principal executive offices located?

DexCom, Inc. was incorporated in Delaware and its principal executive offices are located at 6340 Sequence Drive, San Diego, CA 92121.

From the Filing

0001093557-25-000159.txt : 20250513 0001093557-25-000159.hdr.sgml : 20250513 20250513083100 ACCESSION NUMBER: 0001093557-25-000159 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250509 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250513 DATE AS OF CHANGE: 20250513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 25937356 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 dxcm-20250509.htm 8-K dxcm-20250509 false 0001093557 0001093557 2025-05-09 2025-05-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6340 Sequence Drive , San Diego , CA 92121 (Address of Principal Executive Offices) ( Zip Code) ( 858 ) 200-0200 (Registrant’s Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On May 9, 2025, Jacob S. Leach was promoted to President and Chief Operating Officer of DexCom, Inc. (the “Company”) effective immediately. Mr. Leach reports to Kevin Sayer, who continues to serve as the Company’s Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”). In connection with this promotion, Mr. Leach received a raise to an annual base salary of $800,000 and will be eligible to receive an annual cash performance bonus. The target amount for Mr. Leach’s annual cash performance bonus will be equal to 100% of his annual base salary, with the actu

View on Read The Filing